{"result": "(\"entity\"<|>SITAGLIPTINA<|>PERSON<|>Sitagliptina is a medication used to treat type 2 diabetes by increasing insulin production and decreasing glucose production in the liver.)\n##\n(\"entity\"<|>SAXAGLIPTINA<|>PERSON<|>Saxagliptina is a medication that helps control blood sugar levels in adults with type 2 diabetes.)\n##\n(\"entity\"<|>VILDAGLIPTINA<|>PERSON<|>Vildagliptina is an oral medication for type 2 diabetes that works by increasing insulin release from the pancreas.)\n##\n(\"entity\"<|>LINAGLIPTINA<|>PERSON<|>Linagliptina is a medication used to improve blood sugar control in adults with type 2 diabetes.)\n##\n(\"entity\"<|>ERC<|>EVENT<|>ERC refers to chronic kidney disease, a condition that affects the kidneys' ability to filter waste from the blood.)\n##\n(\"entity\"<|>MANUAL SEEN DE ENDOCRINOLOGÍA<|>ORGANIZATION<|>The Manual SEEN de Endocrinología is a clinical guide that provides information on the management of endocrine disorders, including diabetes and chronic kidney disease.)\n##\n(\"relationship\"<|>SITAGLIPTINA<|>ERC<|>Sitagliptina is used in patients with chronic kidney disease, requiring dose adjustments based on kidney function.<|>8)\n##\n(\"relationship\"<|>SAXAGLIPTINA<|>ERC<|>Saxagliptina is prescribed with caution in patients with chronic kidney disease, with specific dosage recommendations based on kidney function.<|>8)\n##\n(\"relationship\"<|>VILDAGLIPTINA<|>ERC<|>Vildagliptina dosage is adjusted for patients with chronic kidney disease to ensure safety and efficacy.<|>8)\n##\n(\"relationship\"<|>LINAGLIPTINA<|>ERC<|>Linagliptina is noted for its hepatobiliary elimination, which may be relevant for patients with chronic kidney disease.<|>5)\n##\n(\"relationship\"<|>MANUAL SEEN DE ENDOCRINOLOGÍA<|>ERC<|>The Manual SEEN de Endocrinología provides guidelines and recommendations for managing chronic kidney disease in the context of diabetes treatment.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: encia de enfermedad renal crónica (ERC). Sitagliptina, saxagliptina y vildagliptina se                                 El estómago tiene receptores de GIP y GLP-1. La estimulación de los receptores de GLP-\n         eliminan fundamentalmente por vía renal, bien sin metabolizar (sitagliptina) o como meta-                                     1 localizados en el esfínter pilórico causa un vaciamiento gástrico retardado. Además, el\n         bolitos activos (vildagliptina y saxagliptina).                                                                               enlentecimiento del vaciamiento gástrico causa distensión gástrica y estimulación de las\n                                                                                                                                       señales de saciedad.\n         Tabla 7. Limitaciones de uso de los inhibidores de DPP4 según la función renal                                                Aunque se       han   localizado receptores a         nivel renal, su papel       fisiopatológico      no  está   total-\n           Principio activo              ERC leve               ERC moderada             ERC grave            ERC terminal             mente establecido. GLP-1 aumenta la natriuresis al inhibir el cotransportador sodio-hidróge-\n                                        (FG 90-60)                (FG 60-30)            (FG 30-15)              (FG < 15)              no 3 en el túbulo proximal, lo que puede explicar parte de los efectos hipotensores de los\n          Sitagliptina            100 mg/día (FG > 50)             50 mg/día             25 mg/día              25 mg/día              arGLP-1. También se ha descrito un efecto regulatorio sobre el filtrado glomerular, con meca-\n          Vildagliptina           50 mg/12 h (FG > 50)             50 mg/día             50 mg/día              50 mg/día              nismos complejos y que dependerían, en parte, de otros factores, como el control glucémico.\n          Saxagliptina                   5 mg/día                 2,5 mg/día            2,5 mg/día          No recomendado             El péptido natriurético auricular y el sistema renina-angiotensina-aldosterona podrían estar\n          Linagliptina                   5 mg/día                  5 mg/día              5 mg/día               5 mg/día               implicados en estos efectos. En modelos animales, los arGLP-1 tienen efectos nefroprotecto-\n                                                                                                                                       res. Además, existen datos procedentes de estudios clínicos que muestran un efecto positivo\n         Adaptado de: Manual SEEN de Endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo      sobre la progresión de la albuminuria (estudio LEADER, con liraglutida) y sobre la incidencia\n         de.2019).\n                                                                                                                                       de un objetivo renal compuesto (albuminuria de inicio o que progresa, inicio de terapia de\n         De esta forma, el uso de cualquiera de estas tres moléculas en pacientes con ERC re-                                          reemplazo renal, doblar las cifras de creatinina) con semaglutida en el estudio SUSTAIN-6.\n         querirá    un ajuste     de dosis     cuando     el filtrado   glomerular      (FG)   sea inferior     a 50   ml/min.         En el corazón, se ha reportado la presencia de receptores de GLP-1 en el miocardio y en las\n         Para    sitagliptina,    se  recomienda       reducir    la  dosis   a  50   y  25   mg/día     cuando     el FG    sea       células de la capa muscular vascular, por lo que se ha propuesto un efecto vasodilatador de\n         de 50-30 ml/min e inferior a 30 ml/min (incluyendo diálisis), respectivamente. En el caso de                                  GLP-1, que podría ser cardioprotector.\n         vildagliptina, la dosis se reduce a 50 mg/día con FG inferiores a 50 ml/min, incluido ERC\n         en estadio 5. Para saxagliptina se recomienda utilizar 2,5 mg/día en caso de FG inferiores                                    Referencias:\n         a 50 ml/min, salvo en caso de ERC terminal o diálisis, casos en los que hoy día no existe                                     • Ahren B. GLP-1 and extra-islet effects. Horm Metab Res. 2004;36:842-5.\n                                                                                                                                       • Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197-207.\n         indicación en nuestro país. Finalmente, linagliptina tiene una eliminación hepatobiliar, por\n\n\n\n120                                                                                                                                                                                                                                                               121\n---\n                                                                                                                                                                                                                               DIABETES                         2\n\n\n\n     62  ¿Cuál de los siguientes mecanismos no corresponde a los análogos de GLP-1?                                                    64  En relación con los agonistas del receptor de GLP-1 (arGLP-1), señale cuál de las\n         A. Retarda el vaciamiento g\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}